Want to see USAQ full AI Analyst Report?
USAQ Stock Chart & Stats
$0.49
-$0.04(-14.29%)
At close: 4:00 PM EST
$0.49
-$0.04(-14.29%)
Day’s Range― - ―
52-Week Range$0.08 - $1.14
Previous CloseN/A
Volume38.37K
Average Volume (3M)6.57K
Market Cap
$4.77M
Enterprise Value$4.07M
Total Cash (Recent Filing)$362.09K
Total Debt (Recent Filing)$130.18K
Price to Earnings (P/E)10.9
Beta0.86
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding15,032,788
10 Day Avg. Volume9,209
30 Day Avg. Volume6,568
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.21
Price to Sales (P/S)2.54
P/FCF Ratio38.43
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue1.47
Enterprise Value/Gross Profit2.22
Enterprise Value/Ebitda5.94
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilitySustained high gross and positive net margins indicate the digital services model is delivering profitable unit economics. Over 2–6 months this supports reinvestment in product and sales, lowers break-even risk, and reduces dependence on external financing if recurring revenue momentum holds.
Cleaner Balance SheetLow leverage and positive equity materially improve financial flexibility versus recent years of stress. This cleaner capital structure reduces interest and covenant risk, enabling management to fund operational scaling or absorb shortfalls without immediate refinancing over the medium term.
Product & Recurring Revenue ExpansionRapid ISP adoption and new GLP-1 support program expand addressable market into obesity and cardiometabolic care and embed Q-Connect into clinical workflows. These structural product initiatives can increase recurring revenue, stickiness, and lifetime value for provider partners over coming months.
Bears Say
Weak Cash ConversionEarnings have not translated into strong cash generation recently, leaving free cash flow fragile. Over a 2–6 month horizon this limits the company's ability to self-fund growth initiatives and increases the probability of additional capital raises or constrained investment in sales and product scaling.
Uneven Multi-year Track RecordA history of losses and prior balance-sheet stress undermines confidence in sustained operational execution. This historical volatility makes future performance less predictable and raises the risk that current improvements could reverse without durable operational controls or consistent cash flow.
Small Scale/Resource ConstraintsA very small headcount limits internal capacity for sales, provider onboarding, and product development. Scaling recurring-provider adoption and new programs may require hiring or third-party support; constrained resources increase execution risk and could slow durable revenue expansion over the medium term.
QHSLab News
USAQ FAQ
What was QHSLab’s price range in the past 12 months?
QHSLab lowest stock price was $0.08 and its highest was $1.14 in the past 12 months.
What is QHSLab’s market cap?
QHSLab’s market cap is $4.77M.
When is QHSLab’s upcoming earnings report date?
QHSLab’s upcoming earnings report date is Aug 19, 2026 which is in 30 days.
How were QHSLab’s earnings last quarter?
Currently, no data Available
Is QHSLab overvalued?
According to Wall Street analysts QHSLab’s price is currently Overvalued.
Does QHSLab pay dividends?
QHSLab does not currently pay dividends.
What is QHSLab’s EPS estimate?
QHSLab’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does QHSLab have?
QHSLab has 15,032,788 shares outstanding.
What happened to QHSLab’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of QHSLab?
Currently, no hedge funds are holding shares in USAQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
QHSLab
QHSLab, Inc. is a company operating in the medical technology and Software-as-a-Service (SaaS) sectors. Its core focus is on advancing value-based healthcare, medical informatics, and personalized medicine driven by algorithms. The firm also develops digital therapeutic solutions and on-site technologies intended for remote patient oversight, the management of chronic conditions, and proactive health maintenance. Among its offerings is a proprietary cloud-based SaaS platform, also known as QHSLab (Quality Health Score Lab expert system). This system empowers physicians and healthcare organizations to securely record and store electronic patient data. Additionally, QHSLab, Inc. acts as a distributor, providing primary care physicians with AllergiEnd, a product line encompassing diagnostic tools and allergen immunotherapy treatments. All of its solutions are strategically designed to aid in the prevention, early identification, effective management, and potential reversal of chronic diseases. The company was established in 1983 and is headquartered in West Palm Beach, Florida. It operated under the name USA Equities Corp. until April 2022, when it officially rebranded to QHSLab, Inc. The company also maintains a strategic partnership with Medical License Factory, LLC.